EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Circulating tumor DNA in patients with cancer: insights from clinical laboratory

Francisco J Illana iD, Esther Fernández-Galán, José Luis Muñoz-Bravo iD, Laura Valiña Amado, Carme García Martín, Carolina González-Fernández, Sílvia Miró-Cañís, Jaume Trapé, Antonio Martínez-Peinado, Xavier Filella, Alvaro González, Antonio Barco Sánchez und 2 weitere

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · 19.09.2025 · 6 (3) · 259-276

DOI: 10.1515/almed-2025-0010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, online erschienen am 16.06.2025. Verfasst von Francisco J Illana und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Xunta de Galicia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blood-based circulating tumor DNA (ctDNA) analysis has emerged as a highly relevant non-invasive method for molecular profiling of solid tumors, offering valuable information about the genetic landscape of cancer. Somatic mutation analysis of ctDNA is now used clinically to guide targeted therapies for advanced cancers. Recent advancements have also revealed its potential in early detection, prognosis, minimal residual disease assessment, and prediction/monitoring of therapeutic response. In recent years, significant progress has been made with the development of various PCR and NGS-based methods designed for assessing gene variants in ctDNA of patients with cancer. However, despite the transformative possibilities that ctDNA analysis presents, challenges persist. Standardization of preanalytical and analytical protocols, assay sensitivity, and the interpretation of results remain critical hurdles that need to be addressed for the widespread clinical implementation of ctDNA testing. In addition to somatic mutations, emerging studies on DNA methylation (epigenomics) and fragment size patterns (fragmentomics) in several types of biological fluids are yielding promising results as non-invasive biomarkers for effective cancer management. This review addresses the clinical applications of somatic gene variants in ctDNA, emphasizes their potential as cancer biomarkers, and highlights essential factors for successful implementation in clinical laboratories and cancer management.

Schlagwörter

Stichwörter der Autor:innen

biomarkerscancerctDNAliquid biopsysomatic gene variants

Autor:innen und Institutionen

  • Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain.
  • Service of Biochemistry and Molecular Genetics, CDB, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Clinical Analysis Service, General University Hospital of Elche, Elche, Spain.
  • Foundation for the Promotion of Health and Biomedical Research in the Valencia Region (FISABIO), Elche, Spain.
  • Department of Laboratory Medicine, Hospital Universitari Son Espases, Palma, Spain.
  • Group of Advanced Therapies and Biomarkers in Clinical Oncology, Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma, Spain.

ORCID-Profile: Francisco J Illana, José Luis Muñoz-Bravo

Förderung

  • Instituto de Salud Carlos III
  • Xunta de Galicia

Zitieren

APA

Illana, F. J., Fernández-Galán, E., Muñoz-Bravo, J. L., Valiña Amado, L., García Martín, C., González-Fernández, C., Miró-Cañís, S., Trapé, J., Martínez-Peinado, A., Filella, X., González, A., Sánchez, A. B., Díaz-Lagares, A., & Commission on Biological Markers of Cancer of the Spanish Society of Laboratory Medicine (2025). Circulating tumor DNA in patients with cancer: insights from clinical laboratory. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, 6(3), 259-276. https://doi.org/10.1515/almed-2025-0010

Vancouver

Illana FJ, Fernández-Galán E, Muñoz-Bravo JL, Valiña Amado L, García Martín C, González-Fernández C, et al. Circulating tumor DNA in patients with cancer: insights from clinical laboratory. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio. 2025;6(3):259-276. doi:10.1515/almed-2025-0010

BibTeX
@article{Illana2025,
  author = {Illana, Francisco J and Fernández-Galán, Esther and Muñoz-Bravo, José Luis and Valiña Amado, Laura and García Martín, Carme and González-Fernández, Carolina and Miró-Cañís, Sílvia and Trapé, Jaume and Martínez-Peinado, Antonio and Filella, Xavier and González, Alvaro and Sánchez, Antonio Barco and Díaz-Lagares, Angel and Commission on Biological Markers of Cancer of the Spanish Society of Laboratory Medicine, Commission on Biological Markers of Cancer of the Spanish Society of Laboratory Medicine},
  title = {Circulating tumor DNA in patients with cancer: insights from clinical laboratory},
  journal = {Advances in Laboratory Medicine / Avances en Medicina de Laboratorio},
  year = {2025},
  volume = {6},
  number = {3},
  pages = {259--276},
  doi = {10.1515/almed-2025-0010}
}
Kostenlos starten →